Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label trial of disitamab vedotin in HER2-overexpressing advanced or metastatic gastric cancer after at least 2 prior systemic chemotherapy regimens
CTR20202569Phase 3Active
- Sponsor
- RemeGen
- Start
- Mar 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of disitamab vedotin in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by RemeGen. Started Mar 2021; status: active.
02
Drugs
disitamab vedotin
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20202569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202569.